EKTABS Stock Overview
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 4/6 |
Financial Health | 6/6 |
Dividends | 4/6 |
Elekta AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr75.58 |
52 Week High | kr89.31 |
52 Week Low | kr73.51 |
Beta | 1.03 |
1 Month Change | -3.28% |
3 Month Change | -3.28% |
1 Year Change | -12.67% |
3 Year Change | -32.76% |
5 Year Change | -29.83% |
Change since IPO | -77.57% |
Recent News & Updates
Recent updates
Shareholder Returns
EKTABS | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | 0% | 2.8% | 2.0% |
1Y | -12.7% | -8.5% | 4.5% |
Return vs Industry: EKTABS underperformed the UK Medical Equipment industry which returned -9.2% over the past year.
Return vs Market: EKTABS underperformed the UK Market which returned 3% over the past year.
Price Volatility
EKTABS volatility | |
---|---|
EKTABS Average Weekly Movement | n/a |
Medical Equipment Industry Average Movement | 6.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: EKTABS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EKTABS's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1972 | 4,584 | Gustaf Salford | elekta.com |
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care.
Elekta AB (publ) Fundamentals Summary
EKTABS fundamental statistics | |
---|---|
Market cap | kr30.26b |
Earnings (TTM) | kr1.43b |
Revenue (TTM) | kr18.22b |
21.1x
P/E Ratio1.7x
P/S RatioIs EKTABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EKTABS income statement (TTM) | |
---|---|
Revenue | kr18.22b |
Cost of Revenue | kr11.32b |
Gross Profit | kr6.90b |
Other Expenses | kr5.47b |
Earnings | kr1.43b |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
Jun 05, 2024
Earnings per share (EPS) | 3.75 |
Gross Margin | 37.88% |
Net Profit Margin | 7.86% |
Debt/Equity Ratio | 57.2% |
How did EKTABS perform over the long term?
See historical performance and comparison